Table 2.

Immunoreactive Score of Drp1, phospho-Drp1^Ser637, CaMKI, phospho-CaMKI^Thr177 of the tumor and CA125 in relation to clinical factors of patients with ovarian cancer

Variable	Number of patients	Drp1		phospho-Drp1Ser637		CaMKI		phospho-CaMKIThr177		CA125
		mean ± SE	p	mean ± SE	P	mean ± SE	p	mean ± SE	p	mean ± SE	p
Age
< 55	20	10.05 ± 0.52	0.054	4.75 ± 0.66	0.053	9.25 ± 0.55	0.231	1.10 ± 0.24	0.311	792.3 ± 376.3	0.127
≥55	29	11.17 ± 0.35		6.45 ± 0.57		10.10 ± 0.44		0.86 ± 0.21		2141.0 ± 921.6
FIGO stage
I-II	22	10.14 ± 0.46	0.050	5.00 ± 0.58	0.133	8.77 ± 0.52	0.011*	0.73 ± 0.19	0.122	340.8 ± 195.6	< 0.001*
III-IV	27	11.19 ± 0.39		6.37 ± 0.63		10.56 ± 0.42		1.15 ± 0.24		2608.7 ± 987.8
Histology
High-grade serous carcinoma	21	11.24 ± 0.43	0.098	6.62 ± 0.61	0.034*	9.71 ± 0.52	0.974	1.05 ± 0.26	0.502	2832.5 ± 1243.6	0.003*
Non- high-grade serous carcinoma	28	10.32 ± 0.42		5.11 ± 0.61		9.79 ± 0.48		0.89 ± 0.20		658.9 ± 278.7
Completeness of surgical reduction
Complete or optimal	39	10.39 ± 0.36	0.085	5.15 ± 0.46	0.006*	9.46 ± 0.40	0.116	1.03 ± 0.19	0.669	1753.4 ± 712.7	0.264
Suboptimal	10	12.00 ± 0.00		8.10 ± 0.94		10.90 ± 0.57		0.70 ± 0.15		955.0 ± 281.5
Treatment response
Responders	32	10.34 ± 0.40	0.209	5.00 ± 0.47	0.007*	9.25 ± 0.44	0.252	1.00 ± 0.23	0.732	1118 ± 381.5	0.117
Non-responders	11	11.45 ± 0.55		7.82 ± 0.86		10.36 ± 0.70		0.82 ± 0.12		3183 ± 2231
Tumor progression
No progression or platinum-sensitive	35	10.37 ± 0.38	0.056	5.40 ± 0.52	0.160	9.29 ± 0.43	0.030*	0.89 ± 0.16	0.633	1007.7 ± 300.8	0.101
Platinum-resistant	14	11.57 ± 0.43		6.64 ± 0.80		10.93 ± 0.47		1.14 ± 0.39		3047.4 ± 1839

* p < 0.05